Goldman Sachs’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Goldman Sachs’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,062	Closed	-$439K	–	5998
2023 Q4	$439K	Sell	7,062 -237,938	-97%	-$5.91M	﹤0.01%	4835
2023 Q3	$5.44M	Buy	+245,000	New	+$5.14M	﹤0.01%	2914

Goldman Sachs's RYZB Position: Q1 2024 in Review

Goldman Sachs sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 7,062 shares — an estimated $439K sold.

Goldman Sachs first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $5.44M in Q3 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

Goldman Sachs reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Goldman Sachs sold 7,062 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $439K.
Goldman Sachs first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Goldman Sachs's RayzeBio, Inc. Common Stock position peaked at $5.44M in Q3 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.